Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

BACKGROUND: Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-β/PD-L1 bispecific antibody YM101 in immune-excluded tumors. However, YM101 had...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Ming, Niu, Mengke, Wu, Yuze, Ge, Hong, Jiao, Dechao, Zhu, Shuangli, Zhang, Jing, Yan, Yongxiang, Zhou, Pengfei, Chu, Qian, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548169/
https://www.ncbi.nlm.nih.gov/pubmed/36209176
http://dx.doi.org/10.1186/s13045-022-01363-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548169/
https://www.ncbi.nlm.nih.gov/pubmed/36209176
http://dx.doi.org/10.1186/s13045-022-01363-8

Ejemplares similares